^
Association details:
| Biomarker: | MSLN positive |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | MSLN-CAR-T cell therapy (Mesothelin-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer
Published date:
08/23/2023
Excerpt:
We found that MSLN-targeted CAR T cells effectively killed MSLN-positive cancer cells (H9, H226 and Panc-1)...Our results suggest that irinotecan can enhance the antitumor activity of MSLN-targeted CAR T cells, and offer a promising combination therapy strategy for MSLN-positive solid tumors.
DOI:
10.1007/s00432-023-05279-9
